United States Patent 6,455,269
Toombs September 24, 2002
--------------------------------------------------------------------------------
Method for localized administration of fibrinolytic metalloproteinases
Abstract
A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of .alpha..sub.2 -macroglobulin in the circulating blood.
--------------------------------------------------------------------------------
Inventors: Toombs; Christopher F. (Camarillo, CA)
Assignee: Amgen, Inc. (Thousand Oaks, CA)
Appl. No.: 466276
Filed: December 17, 1999
United States Patent 6,440,414
Kendrick , et al. August 27, 2002
--------------------------------------------------------------------------------
Pharmaceutical compositions of fibrinolytic agent
Abstract
Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the lyophilized composition, and a kit and method for reconstituting the lyophilized composition are described herein.
--------------------------------------------------------------------------------
Inventors: Kendrick; Brent S. (Moorpark, CA); Peterson; Brian A. (Simi Valley, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Appl. No.: 411335
Filed: October 1, 1999
United States Patent 6,440,414
Kendrick , et al. August 27, 2002
--------------------------------------------------------------------------------
Pharmaceutical compositions of fibrinolytic agent
Abstract
Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the lyophilized composition, and a kit and method for reconstituting the lyophilized composition are described herein.
--------------------------------------------------------------------------------
Inventors: Kendrick; Brent S. (Moorpark, CA); Peterson; Brian A. (Simi Valley, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Appl. No.: 411335
Filed: October 1, 1999
(etc.)
a blurb from the Hyseq website........
World Class Partner
Alfimeprase was identified through a research program at Amgen, who partnered with Hyseq in January 2002 for development and commercialization. Under the terms of the collaboration, Hyseq will lead development and be responsible for all clinical development activities and Amgen will be responsible for manufacturing activities. Amgen will have the option to lead the commercialization efforts in which both companies may participate. |
